Oncology

A cancer diagnosis carries incredible burden. That’s why we pursue new therapies, expand access to medicines, provide support, and learn from patients every day.
Schlomit, multiple myeloma, Israel
Schlomit, multiple myeloma, Israel
Until we find cures, we’ll continue to chase miracles of science that transform treatment and care, while addressing the real needs of people living with cancer, such as quality of life.
Peter Adamson

Peter Adamson

Head of Oncology Development

Did you know?

18.1 million

Number of cancer cases around the world.(1)

2nd

Cancer is the second leading cause of death globally.(2)

21%

Projected increase in EU cancer cases by 2040.(3)
Danielle, multiple myeloma, US
Danielle, multiple myeloma, US

Our commitment to oncology

We’re charging ahead, building on our rich legacy in oncology. With a growing pipeline and renewed commitment to advancing transformative therapies, we’re determined to help improve outcomes and the lives of people living with many different types of cancer.

Thomas, lung cancer, Germany

Our oncology focus

We’re building a differentiated oncology pipeline, focusing our research on areas of high unmet need. Because our goal is to go beyond the expected and transform the treatment of cancer.

Ron, cutaneous squamous cell carcinoma, US
Ron, cutaneous squamous cell carcinoma, US

What’s next in oncology?

With new technologies unlocking a world of possibilities, we’re confident the investigational medicines in our pipeline will be more effective in combatting cancer and safer for patients.

Because our fight is not just against cancer. It’s for people and their quality of life.

Explore more

Oncology Research and Development

Clinical Trials and Results

References

  1. World Cancer Research Fund International (2021) Worldwide cancer data. Accessed October 2022.
  2. World Health Organization (2022) Cancer. Accessed October 2022
  3. European Commission (2022). EU Science Hub. European Cancer Information System: 21% increase in new cancer cases by 2040. Accessed October 2022

Page updated December 2023

MAT-GLB-2100976 v3.0-5/2023